Stellar Pharmaceuticals gets Uracyst patent in Japan

Stellar Pharmaceuticals (OTCQB:SLXCF) has received a patent from the Japan Patent Office for one of its lead products, Uracyst,  covering the treatment of cystitis and other related conditions by instillation into the bladder of a dose comprising of at least 350 mg in a volume of from 10 ml to 100 ml. The patent will [...]

Stellar taps familiar face as advisory consultant for U.S. market

Stellar Pharmaceuticals (OTCQB:SLXCF) has engaged the services of Advisory Associates (AAI) as an advisory consultant to locate leads and assist in negotiating a license deal for the company’s products, NeoVisc and Uracyst for the U.S. market. “I am pleased that we were able to enter into this agreement with AAI given its experience and proven [...]

Korea clears Stellar’s Uracyst

The Korean Food and Drug Administration has approved Stellar Pharmaceuticals’ (OTCBB:SLXCF) Uracyst for the treatment of interstitial cystitis/painful bladder syndrome. Uracyst will be distributed in South Korea by Stellar’s licensee in that market, Jeilmedix Pharmaceutical, which has a major focus in urology, the primary target market for Uracyst. Stellar expects to deliver the initial commercial order to [...]

Stellar analyzing high placebo response rate in pilot study

Stellar Pharmaceuticals (OTCBB:SLXCF) believes that an “anomalously high placebo response rate may be a possible reason for the primary efficacy endpoints … not having been met” in Watson Pharma’s (NYSE:WPI) pilot study of Stellar’s Uracyst drug for the treatment of interstitial cystitis/painful bladder syndrome (IC/PBS) in the U.S. The company said it plans to continue [...]

You asked a CEO

Four weeks ago, we asked you what’s on your mind. Specifically, what would you like to “Ask a CEO?”  Frankly, we were heartened and surprised by your response. So as promised, this week’s Feature, which coincides with the first anniversary of biotuesdays.com’s launch, is a rundown of the questions and the answers we received. We [...]

Stellar signs Uracyst distributor in Spain

Stellar Pharmaceuticals (OTCBB: SLXCF) has signed a license agreement with Laboratorios Inibsa S.A. for the sale and distribution in Spain of one of its lead products, Uracyst, for the treatment of interstitial cystitis/painful bladder syndrome. Uracyst already has CE mark approval in Europe and Inibsa is expected to launch the drug in the fourth quarter [...]

Stellar gets Uracyst patents in China and U.S.

Stellar Pharmaceuticals (OTCBB: SLXCF) has been issued patents for Uracyst, one of its lead products for the treatment of interstitial cystitis/painful bladder syndrome, by both the Chinese Patent Office and the U.S. Patent and Trademark Office. The Chinese patent covers pharmaceutical compositions that comprise the greater and superior dosage size of chondroitin sulfate, and the [...]

Stellar allowed Uracyst patent in U.S.

Stellar Pharmaceuticals (OTCBB: SLXCF) has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to its Uracyst treatment of interstitial cystitis/painful bladder syndrome.  The patent will expire in 2024. The issuance of the patent triggers a milestone payment of $1.3 million (U.S.) from Stellar’s U.S. marketing and distribution [...]

Cowen ups Watson to outperform; Stellar’s Uracyst high in rationale

Cowen & Co. upgraded Watson Pharmaceuticals (NYSE:WPI) to “outperform” from “neutral,” saying it has “significantly underappreciated its brand pipeline” and making an earlier reference to the potential of Stellar Pharmaceuticals’ (OTCBB: SLXCF) Uracyst drug for painful interstitial cystitis/painful bladder syndrome. Analyst Ken Cacciatore writes that Uracyst, which is sold in Canada by Stellar and in [...]

Stellar signs distributor for Uracyst in Germany and Austria

After tapping into the Portugal market earlier this week, Stellar Pharmaceuticals (OTCBB: SLXCF) signed a license agreement with medac GmbH for the distribution and sale of its Uracyst treatment for interstitial cystitis/painful bladder syndrome in Germany and Austria. “This agreement not only represents an important revenue opportunity for Stellar and medac, but also offers hope [...]

Next Page »